EUVIMEDEUVIMED entdecken
Crossref

Carphology

A Fo Ben

Practical Neurology · 2026-12 · 26 (6) · 640-640

DOI: 10.1136/pn-2026-005503 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Practical Neurology, online erschienen am 13.11.2026. Verfasst von A Fo Ben.

AbstractBibliografische AngabenZitieren

Abstract (Originalsprache)

A phase 3 trial of rituximab vs ocrelizumab in newly diagnosed relapsing-remitting MS gave a remarkably diplomatic result.Rituximab was non-inferior to ocrelizumab in suppressing MRI disease activity between 6 and 24 months.Relapse, disability and cognitive outcomes were similar, although analyses were underpowered to exclude clinically important differences.The separation came with infection rates: 82% with rituximab vs 69% with ocrelizumab.Most were mild, but with no long-term safety data.However, rituximab's lower acquisition cost looks different when including recurrent infections.Patients might end up paying the difference in coughs and antibiotics.

Zitieren

APA

Ben, A. F. (2026). Carphology. Practical Neurology, 26(6), 640-640. https://doi.org/10.1136/pn-2026-005503

Vancouver

Ben AF. Carphology. Practical Neurology. 2026;26(6):640-640. doi:10.1136/pn-2026-005503

BibTeX
@article{Ben2026,
  author = {Ben, A Fo},
  title = {Carphology},
  journal = {Practical Neurology},
  year = {2026},
  volume = {26},
  number = {6},
  pages = {640--640},
  doi = {10.1136/pn-2026-005503}
}
Kostenlos starten →